Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AXGNNASDAQ:LUNGNASDAQ:NPCENASDAQ:OM On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAXGNAxoGen$9.50+2.2%$12.85$6.59▼$21.00$433.31M1.05478,692 shs228,538 shsLUNGPulmonx$2.69-2.4%$3.73$2.62▼$9.37$108.10M0.52307,536 shs145,200 shsNPCENeuroPace$10.57-0.3%$12.83$5.45▼$18.98$347.18M2.03170,937 shs82,058 shsOMOutset Medical$19.33-1.2%$15.97$5.85▼$72.60$341.55M2.15122,714 shs141,850 shs7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAXGNAxoGen0.00%-7.47%-19.71%-47.57%+29.93%LUNGPulmonx0.00%-12.42%-17.91%-64.61%-53.35%NPCENeuroPace0.00%-5.61%-41.08%-11.81%+63.08%OMOutset Medical0.00%-3.50%+0.31%+94.73%-64.16%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAXGNAxoGen2.7069 of 5 stars3.52.00.00.02.72.50.6LUNGPulmonx3.525 of 5 stars3.35.00.00.02.63.30.6NPCENeuroPace3.597 of 5 stars3.45.00.00.01.84.20.6OMOutset Medical1.3946 of 5 stars3.53.00.00.00.00.80.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAXGNAxoGen 3.00Buy$22.20133.81% UpsideLUNGPulmonx 2.63Moderate Buy$11.53329.24% UpsideNPCENeuroPace 2.83Moderate Buy$15.5046.66% UpsideOMOutset Medical 3.00Buy$27.0039.68% UpsideCurrent Analyst Ratings BreakdownLatest LUNG, AXGN, NPCE, and OM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/28/2025NPCENeuroPaceHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$18.005/22/2025LUNGPulmonxCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$6.50 ➝ $4.155/21/2025OMOutset MedicalRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSector Perform ➝ Sector Perform$14.00 ➝ $21.005/15/2025OMOutset MedicalScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy5/14/2025NPCENeuroPaceJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$14.00 ➝ $16.005/14/2025NPCENeuroPaceCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$17.00 ➝ $17.005/13/2025AXGNAxoGenCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$26.00 ➝ $24.005/8/2025OMOutset MedicalRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetSector Perform ➝ Sector Perform$12.00 ➝ $14.005/1/2025LUNGPulmonxCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$16.00 ➝ $15.005/1/2025LUNGPulmonxPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$10.00 ➝ $9.005/1/2025LUNGPulmonxD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$17.00 ➝ $17.00(Data available from 6/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAXGNAxoGen$187.34M2.31N/AN/A$2.36 per share4.02LUNGPulmonx$83.79M1.29N/AN/A$2.17 per share1.24NPCENeuroPace$84.31M4.11N/AN/A$0.27 per share39.14OMOutset Medical$113.69M3.01N/AN/A$7.49 per share2.58Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAXGNAxoGen-$9.96M-$0.15N/AN/AN/A-3.68%-7.09%-3.67%8/14/2025 (Estimated)LUNGPulmonx-$56.39M-$1.44N/AN/AN/A-65.27%-63.69%-34.94%7/30/2025 (Estimated)NPCENeuroPace-$27.14M-$0.84N/AN/AN/A-29.42%-190.84%-25.08%8/12/2025 (Estimated)OMOutset Medical-$127.98M-$29.15N/A∞N/A-98.74%-143.62%-37.50%8/6/2025 (Estimated)Latest LUNG, AXGN, NPCE, and OM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025NPCENeuroPace-$0.26-$0.21+$0.05-$0.21$21.85 million$22.52 million5/7/2025Q1 2025LUNGPulmonx-$0.37-$0.36+$0.01-$0.36$22.03 million$22.54 million5/7/2025Q1 2025OMOutset Medical-$0.97-$3.66-$2.69-$3.66$27.81 million$29.75 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAXGNAxoGenN/AN/AN/AN/AN/ALUNGPulmonxN/AN/AN/AN/AN/ANPCENeuroPaceN/AN/AN/AN/AN/AOMOutset MedicalN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAXGNAxoGen0.634.282.65LUNGPulmonx0.384.974.29NPCENeuroPace2.466.635.70OMOutset Medical0.578.376.74Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAXGNAxoGen80.29%LUNGPulmonx91.04%NPCENeuroPace78.83%OMOutset MedicalN/AInsider OwnershipCompanyInsider OwnershipAXGNAxoGen2.78%LUNGPulmonx6.80%NPCENeuroPace20.50%OMOutset Medical2.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAXGNAxoGen45045.54 million44.28 millionOptionableLUNGPulmonx25040.26 million37.52 millionOptionableNPCENeuroPace17032.80 million26.08 millionOptionableOMOutset Medical52017.72 million17.30 millionNot OptionableLUNG, AXGN, NPCE, and OM HeadlinesRecent News About These CompaniesOutset Medical (NASDAQ:OM) Upgraded by Wall Street Zen to "Hold" RatingJune 7, 2025 | marketbeat.comOutset Medical to Present at the Goldman Sachs 46th Annual Global Healthcare ConferenceJune 5, 2025 | globenewswire.comFormer Shockwave CFO joins Outset Medical in the same roleJune 4, 2025 | massdevice.comOutset Medical Appoints Renee Gaeta as Chief Financial OfficerJune 3, 2025 | globenewswire.comOutset Medical (NASDAQ:OM) Stock Price Down 9.7% - Here's WhyJune 1, 2025 | marketbeat.comShort Interest in Outset Medical, Inc. (NASDAQ:OM) Drops By 49.8%May 31, 2025 | marketbeat.comRoyal Bank of Canada Forecasts Strong Price Appreciation for Outset Medical (NASDAQ:OM) StockMay 23, 2025 | marketbeat.comOutset Medical, Inc. (NASDAQ:OM) CFO Nabeel Ahmed Sells 584 SharesMay 17, 2025 | insidertrades.comOutset Medical Appoints Industry Veteran Kevin O’Boyle to its Board of DirectorsMay 15, 2025 | uk.finance.yahoo.comOutset Medical Appoints Industry Veteran Kevin O'Boyle to its Board of DirectorsMay 14, 2025 | globenewswire.comOutset Medical to Present at RBC Global Healthcare ConferenceMay 9, 2025 | globenewswire.comOutset Medical, Inc. (OM) Q1 2025 Earnings Call TranscriptMay 7, 2025 | seekingalpha.comOutset Medical, Inc. (OM) Reports Q1 Loss, Tops Revenue EstimatesMay 7, 2025 | zacks.comOutset Medical First-Quarter Results Demonstrate Strong Growth in Console and Recurring Revenue as Gross Margin Expanded and Cash Use DeclinedMay 7, 2025 | globenewswire.comOUTSET MEDICAL ALERT: Bragar Eagel & Squire, P.C. is Investigating Outset Medical, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the FirmApril 29, 2025 | globenewswire.comDoes Outset Medical (OM) Have the Potential to Rally 71.66% as Wall Street Analysts Expect?April 21, 2025 | zacks.comOutset Medical, Inc. Announces Q1 2025 Financial Results Release and Conference Call DetailsApril 16, 2025 | quiverquant.comOutset Medical: The Worst Is Over, But Execution Risk Remains HighApril 16, 2025 | seekingalpha.comAnalysts Conflicted on These Healthcare Names: Outset Medical (OM) and AptarGroup (ATR)April 16, 2025 | markets.businessinsider.comPainful week for individual investors invested in Outset Medical, Inc. (NASDAQ:OM) after 18% drop, institutions also suffered lossesApril 10, 2025 | finance.yahoo.comWall Street Analysts Predict an 188.63% Upside in Outset Medical (OM): Here's What You Should KnowApril 2, 2025 | zacks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Defense Stocks That Will Profit From a Golden DomeBy Chris Markoch | May 30, 2025View 3 Defense Stocks That Will Profit From a Golden DomeAnalysts Think These Stocks Could More Than Double in ValueBy Nathan Reiff | May 23, 2025View Analysts Think These Stocks Could More Than Double in ValueIntel’s Turnaround May Be the Best Bet No One’s WatchingBy Jeffrey Neal Johnson | May 30, 2025View Intel’s Turnaround May Be the Best Bet No One’s WatchingBullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsBy Thomas Hughes | May 27, 2025View Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsSouthwest Airlines: Short Interest Plunges—Should You Buy?By Gabriel Osorio-Mazilli | June 17, 2025View Southwest Airlines: Short Interest Plunges—Should You Buy?LUNG, AXGN, NPCE, and OM Company DescriptionsAxoGen NASDAQ:AXGN$9.49 +0.21 (+2.21%) As of 01:30 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.AxoGen, Inc., together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and AxoTouch two-point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. The company provides its products to hospitals, surgery centers, and military hospitals, plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons. AxoGen, Inc. is headquartered in Alachua, Florida.Pulmonx NASDAQ:LUNG$2.68 -0.07 (-2.36%) As of 01:29 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. It also offers StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis service that offers information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for the treatment with Zephyr Valves. The company serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia-Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.NeuroPace NASDAQ:NPCE$10.57 -0.03 (-0.29%) As of 01:30 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. The company sells its products to hospital facilities for initial RNS system implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California.Outset Medical NASDAQ:OM$19.33 -0.24 (-1.23%) As of 01:29 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Outset Medical, Inc., a medical technology company, engages in the development of a hemodialysis system for hemodialysis in the United States. The company offers Tablo Hemodialysis System, a compact console with integrated water purification, on-demand dialysate production, and software and connectivity capabilities for dialysis care in acute and home settings; and manufactures, supports, and distributes for Tablo console, Tablo cartridge, and other consumables. It also provides Tablo Data Ecosystem, including TabloHub, a customer-facing portal; MyTablo, a patient-facing portal; and TabloDash, an internal data analytics platform. The company was formerly known as Home Dialysis Plus, Ltd. and changed its name to Outset Medical, Inc. in January 2015. Outset Medical, Inc. was incorporated in 2003 and is headquartered in San Jose, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Super Micro Computer Stock's Rally Backed by Strong Financials Forget the Fed: Home Depot Is the Real Gauge of the U.S. Consumer 3 Reasons AMD Could Be the Hottest Stock of the Summer Analysts Keep Boosting Taiwan Semiconductor Stock—Here's Why Robinhood Director Sells Millions, But HOOD Stock Eyes Gains Coinbase Stock Pops as Senate Passes GENIUS Stablecoin Bill Dan Ives Just Unveiled His AI ETF—Does It Live Up to the Hype? Intel's Turnaround Strategy Shifts From Planning to Attack Mode Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
